Killen Group’s GSK GSK Stock Holding History

Killen Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$20.8M	Sell	409,458 -45,021	-10%	-$2.24M	2.4%	8
2015 Q4	$22.9M	Sell	454,479 -10,559	-2%	-$538K	2.37%	6
2015 Q3	$22.4M	Sell	465,038 -29,148	-6%	-$1.52M	2.09%	8
2015 Q2	$25.7M	Buy	494,186 +464	+0.1%	+$26.1K	1.95%	10
2015 Q1	$28.5M	Buy	493,722 +91,424	+23%	+$5.24M	2.04%	8
2014 Q4	$21.5M	Buy	402,298 +115,716	+40%	+$6.47M	1.4%	24
2014 Q3	$16.5M	Buy	286,582 +139	+0%	+$8.52K	0.92%	47
2014 Q2	$19.1M	Sell	286,443 -135	-0%	-$9.14K	1%	35
2014 Q1	$19.1M	Buy	286,578 +25,803	+10%	+$1.74M	1.05%	32
2013 Q4	$17.4M	Buy	260,775 +11,068	+4%	+$718K	1%	45
2013 Q3	$15.7M	Buy	249,707 +6,260	+3%	+$403K	0.93%	48
2013 Q2	$15.2M	Buy	+243,447	New	+$15.5M	1.08%	41

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Killen Group's GSK Position: Q1 2016 in Review

Killen Group reduced its GSK (GSK) stake by 9.9% in Q1 2016, selling an estimated $2.24M and leaving 409,458 shares worth $20.8M. The position accounts for 2.4% of the portfolio, ranked #8.

Killen Group first reported a position in GSK in Q2 2013 and has held it in 12 quarters since. The position peaked at $28.5M in Q1 2015. 726 funds tracked by Wall St. Rank hold GSK as of Q1 2016.

Killen Group held 409,458 shares of GSK worth $20.8M as of Q1 2016.
Killen Group sold 45,021 GSK shares in Q1 2016, an estimated $2.24M.
GSK made up 2.4% of Killen Group's portfolio in Q1 2016, its #8 holding.
Killen Group first reported a position in GSK in Q2 2013 and has held it in 12 quarters since.
Killen Group's GSK position peaked at $28.5M in Q1 2015.
726 funds tracked by Wall St. Rank held GSK as of Q1 2016.

Based on Killen Group's 13F filing for Q1 2016, filed 27 Apr 2016.